| scholarly article | Q13442814 |
| P50 | author | Myron S. Cohen | Q16733099 |
| Barton Haynes | Q4865631 | ||
| Lynn Morris | Q70377150 | ||
| Sengeziwe Sibeko | Q72617850 | ||
| Mark K. Louder | Q87913394 | ||
| Stephen D Schmidt | Q89034614 | ||
| Rebecca M Lynch | Q90663182 | ||
| Jennifer L Kirchherr | Q114406376 | ||
| Salim Abdool Karim | Q18161438 | ||
| Hanneke Schuitemaker | Q28606860 | ||
| Gary Nabel | Q29446276 | ||
| Elin S Gray | Q56637089 | ||
| John R. Mascola | Q63302442 | ||
| David C. Montefiori | Q63302725 | ||
| Georgia D. Tomaras | Q63663866 | ||
| P2093 | author name string | Zhi-Yong Yang | |
| Kelly Soderberg | |||
| Zelda Euler | |||
| Lillian Tran | |||
| CHAVI 001 Clinical Team Members | |||
| Rebecca Dersimonian | |||
| P2860 | cites work | Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro | Q24563642 |
| Increasing the potency and breadth of an HIV antibody by using structure-based rational design | Q24631510 | ||
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site | Q27316899 | ||
| Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates | Q27629806 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41 | Q28236154 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library | Q31031532 | ||
| Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals | Q33526340 | ||
| Characteristics of the earliest cross-neutralizing antibody response to HIV-1. | Q33798076 | ||
| Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting | Q34042758 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection | Q34228730 | ||
| Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope | Q34348303 | ||
| The immune response during acute HIV-1 infection: clues for vaccine development | Q34614862 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection | Q35076717 | ||
| Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection | Q35363127 | ||
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | Q35382871 | ||
| Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design | Q35868076 | ||
| Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans | Q36641374 | ||
| Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding | Q36649958 | ||
| Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody | Q36821885 | ||
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. | Q36974754 | ||
| Broad HIV-1 neutralization mediated by CD4-binding site antibodies | Q36977635 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection | Q37273195 | ||
| Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors | Q37333772 | ||
| Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 | ||
| Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment | Q37410770 | ||
| Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. | Q41582091 | ||
| Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression | Q56886558 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 7588-7595 | |
| P577 | publication date | 2012-05-09 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | The development of CD4 binding site antibodies during HIV-1 infection | |
| P478 | volume | 86 |
| Q27302081 | A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen |
| Q36466846 | A Single Residue within the V5 Region of HIV-1 Envelope Facilitates Viral Escape from the Broadly Neutralizing Monoclonal Antibody VRC01 |
| Q35706462 | A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site |
| Q33808304 | Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals |
| Q36702114 | Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens |
| Q40463159 | An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. |
| Q34784825 | An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses. |
| Q37680009 | An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. |
| Q36118373 | Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses |
| Q39108710 | B-cell responses to HIV infection |
| Q36290038 | Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. |
| Q33594304 | Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals |
| Q91812746 | Broadly Neutralizing Antibodies against HIV: Back to Blood |
| Q35894094 | Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort |
| Q53825583 | Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. |
| Q27644501 | Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus |
| Q34114798 | Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies |
| Q60951055 | Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India |
| Q38793711 | Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques |
| Q34368932 | Deep Panning: steps towards probing the IgOme |
| Q36298503 | Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. |
| Q37069837 | Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. |
| Q36736392 | Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques |
| Q27022652 | Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection |
| Q89790317 | Diversity and function of maternal HIV-1-specific antibodies at the time of vertical transmission |
| Q37171570 | Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques |
| Q37624842 | Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption |
| Q93037487 | Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection |
| Q34133551 | Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. |
| Q34511092 | Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm |
| Q36750045 | Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies |
| Q34594513 | Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. |
| Q37426168 | Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses |
| Q55359818 | Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains. |
| Q50420466 | Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site |
| Q38764547 | Germline-targeting immunogens |
| Q35585401 | Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals |
| Q41919287 | HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site |
| Q56913214 | HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes |
| Q28647225 | HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers |
| Q35640998 | HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies |
| Q89746983 | HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice |
| Q47555844 | HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis |
| Q37484124 | HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study |
| Q56909688 | HLA-C downregulation by HIV-1 adapts to host HLA genotype |
| Q27679031 | Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites |
| Q57117718 | IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells |
| Q39108796 | Identification and specificity of broadly neutralizing antibodies against HIV |
| Q35592911 | Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual |
| Q40103798 | Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies |
| Q35171701 | Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization |
| Q34434913 | Immunogenetics of small ruminant lentiviral infections |
| Q42280562 | Immunogenic properties of a lettuce-derived C4(V3)6 multiepitopic HIV protein |
| Q90466213 | Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity |
| Q47118310 | Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations |
| Q36309003 | Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection |
| Q36862088 | Maturational characteristics of HIV-specific antibodies in viremic individuals |
| Q28483205 | Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India |
| Q34055377 | Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production |
| Q36603515 | Neutralizing antibodies to HIV-1 induced by immunization. |
| Q27675468 | Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 |
| Q42215329 | Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. |
| Q91960739 | Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan |
| Q36051764 | Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response |
| Q86408281 | Report of the Cent Gardes HIV Vaccine Conference the B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5–7 November 2012 |
| Q36670538 | Role of IL-21 and IL-21 Receptor on B Cells in HIV Infection |
| Q90401095 | Seeing Is Believing: Nuclear Imaging of HIV Persistence |
| Q92480393 | Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity |
| Q27643993 | Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors |
| Q38811547 | Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting |
| Q30238730 | Survivors Remorse: antibody-mediated protection against HIV-1. |
| Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
| Q35686970 | The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection |
| Q27680688 | The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies |
| Q34441935 | Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization |
| Q55312137 | Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera. |
| Q47215738 | Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models |
| Q92883419 | Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins |
| Q35034268 | Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes |
| Q92916578 | Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells |
Search more.